14Oct 2017

A REVIEW ON APPROACHES TO DIAGNOSE THE AUTISM SPECTRUM DISORDER: THE NEED OF THE HOUR.

  • Department of Biotechnology, ManavRachna International University, Faridabad, India.
  • Accendere Knowledge Management Services Private Ltd., India.
Crossref Cited-by Linking logo

Plum Print visual indicator of research metrics
  • Captures
    • Readers: 8
see details

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Autism spectrum disorder is a complex multigenic neurodevelopmental disorder with a prevalence of 1 in 68 children affecting male more than female (1 in 42 boys and 1 in 189 girls). In present study, focus has been put forth on several aspects of autism diagnosis. To that end association of certain biomarkers such as oxytocin, vasopressin, retinoic acid and 5-hydroxymethylcytosine has been discussed. As autism is also known to be caused by parental influence, prenatal stress, improper uterine environment, drugs taken during pregnancy and role of vertically transmitted diseases has also been given importance. Biological cause correlates autism with various other disorders such as schizophrenia, fragile X syndrome and mitochondrial disorders. Moreover, autism is known to be caused by more than 100 genes. Thus, a thorough emphasis has been given to highlight inter and intra-association of all the relevant diseases and biomarkers to give more insight regarding diagnostic measures of autism.

  1. Muhle R, Trentacoste SV, RapinI. The genetics of autism. Pediatrics. 2004; 113:e472-486.
  2. Goldani AA, Downs SR, Widjaja F, Lawton B, Hendren RL. Biomarkers in autism. Frontiers in psychiatry. 2014; 5:100.
  3. Stessman HA, Bernier R, Eichler EE. A genotype-first approach to defining the subtypes of a complex disease. Cell. 2014; 156:872-877.
  4. State MW, Levitt P. The conundrums of understanding genetic risks for autism spectrum disorders. Nature neuroscience. 2011; 14:1499-1506.
  5. Belmonte MK, Bourgeron T. Fragile X syndrome and autism at the intersection of genetic and neural networks. Nature neuroscience. 2006; 9:1221-1225.
  6. Murdoch JD, State MW. Recent developments in the genetics of autism spectrum disorders. Current opinion in genetics & development. 2013; 23:310-315.
  7. Chango A, De Courcy GP, Boisson F, Guilland JC, Barbe F, Perrin MO, Christides JP, Rabhi K, Pfister M, Galan P, Hercberg S. 5, 10-methylenetetrahydrofolate reductase common mutations, folate status and plasma homocysteine in healthy French adults of the Supplementation en Vitamines et MinerauxAntioxydants (SU. VI. MAX) cohort. British Journal of Nutrition. 2000; 84:891-896.
  8. Lee TL, Raygada MJ, Rennert OM. Integrative gene network analysis provides novel regulatory relationships, genetic contributions and susceptible targets in autism spectrum disorders. Gene. 2012; 496:88-96.
  9. Wong CC, Meaburn EL, Ronald A, Price TS, Jeffries AR, Schalkwyk LC, Plomin R, Mill J. Methylomic analysis of monozygotic twins discordant for autism spectrum disorder and related behavioural traits. Molecular psychiatry. 2014; 19:495-503.
  10. Ma DK, Marchetto MC, Guo JU, Ming GL, Gage FH, Song H. Epigenetic choreographers of neurogenesis in the adult mammalian brain. Nature neuroscience. 2010; 13:1338-1344.
  11. Gregory SG, Connelly JJ, Towers AJ, Johnson J, Biscocho D, Markunas CA, Lintas C, Abramson RK, Wright HH, Ellis P, Langford CF. Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC medicine. 2009; 7:62.
  12. Nagarajan R, Hogart A, Gwye Y, Martin MR, LaSalle JM. Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation. Epigenetics. 2006; 1:172-182.
  13. Shulha HP, Cheung I, Whittle C, Wang J, Virgil D, Lin CL, Guo Y, Lessard A, Akbarian S, Weng Z. Epigenetic signatures of autism: trimethylated H3K4 landscapes in prefrontal neurons. Archives of general psychiatry. 2012; 69:314-324.
  14. Wong CC, Caspi A, Williams B, Craig IW, Houts R, Ambler A, Moffitt TE, Mill J. A longitudinal study of epigenetic variation in twins. Epigenetics. 2010; 5:516-526.
  15. Lowe TL, Tanaka K, Seashore MR, Young JG, Cohen DJ. Detection of phenylketonuria in autistic and psychotic children. JAMA. 1980; 243:126-128.
  16. Bottini N, De Luca D, Saccucci P, Fiumara A, Elia M, Porfirio MC, Lucarelli P, Curatolo P. Autism: evidence of association with adenosine deaminase genetic polymorphism. Neurogenetics. 2001; 3:111-113.
  17. Zaffanello M, Zamboni G, Fontana E, Zoccante L, Tat? L. A case of partial biotinidase deficiency associated with autism. Child Neuropsychology. 2003; 9:184-188.
  18. Moretti P, Peters SU, Del Gaudio D, Sahoo T, Hyland K, Bottiglieri T, Hopkin RJ, Peach E, Min SH, Goldman D, Roa B. Brief report: autistic symptoms, developmental regression, mental retardation, epilepsy, and dyskinesias in CNS folate deficiency. Journal of autism and developmental disorders. 2008; 38:1170-1177.
  19. Wang L, Angley MT, Gerber JP, Sorich MJ. A review of candidate urinary biomarkers for autism spectrum disorder. Biomarkers. 2011; 16:537-552.
  20. Thomas RH, Foley KA, Mepham JR, Tichenoff LJ, Possmayer F, MacFabe DF. Altered brain phospholipid and acylcarnitine profiles in propionic acid infused rodents: further development of a potential model of autism spectrum disorders. Journal of neurochemistry. 2010; 113:515-529.
  21. MacFabe D. Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders. Microbial ecology in health and disease. 2012; 23:19260.
  22. Frustaci A, Neri M, Cesario A, Adams JB, Domenici E, DallaBernardina B, Bonassi S. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radical Biology and Medicine. 2012; 52:2128-2141.
  23. Damodaran LP, Arumugam G. Urinary oxidative stress markers in children with autism. Redox Report. 2011; 16:216-222.
  24. Gorrindo P, Lane CJ, Lee EB, McLaughlin B, Levitt P. Enrichment of Elevated Plasma F 2t-Isoprostane Levels in Individuals with Autism Who Are Stratified by Presence of Gastrointestinal Dysfunction. PloS one. 2013; 8:e68444.
  25. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Molecular psychiatry. 2012; 17:290-314.
  26. Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, Cohen BH. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics. 2007; 120:1326-1333.
  27. Poling JS, Frye RE, Shoffner J, Zimmerman AW. Developmental regression and mitochondrial dysfunction in a child with autism. Journal of child neurology. 2006; 21:170-172.
  28. Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M. How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis. Neurotoxicology. 2008; 29:190-201.
  29. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. The American journal of clinical nutrition. 2004; 80:1611-1617.
  30. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain, behavior, and immunity. 2011; 25:40-45.
  31. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain, behavior, and immunity. 2012; 26:383-392.
  32. AshwoodP, Wills S, Van de Water J. The immune response in autism: a new frontier for autism research. Journal of leukocyte biology. 2006; 80:1-5.
  33. Al-Ayadhi LY, Mostafa GA. A lack of association between elevated serum levels of S100B protein and autoimmunity in autistic children. Journal of neuroinflammation. 2012; 9:54.
  34. Singh VK. Phenotypic expression of autoimmune autistic disorder (AAD): a major subset of autism.Annals of Clinical Psychiatry. 2009; 21:148-161.
  35. Connolly AM, Chez MG, Pestronk A, Arnold ST, Mehta S, Deuel RK. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. The Journal of pediatrics. 1999; 134:607-613.
  36. Ashwood P, Van de Water J. Is autism an autoimmune disease?. Autoimmunity Reviews. 2004; 3:557-562.
  37. Cabanlit M, Wills S, Goines P, Ashwood P, Van De Water J. Brain‐Specific Autoantibodies in the Plasma of Subjects with Autistic Spectrum Disorder. Annals of the New York Academy of Sciences. 2007; 1107:92-103.
  38. Mostafa GA, AL-ayadhi LY. Increased serum levels of anti-ganglioside M1 auto-antibodies in autistic children: relation to the disease severity. Journal of neuroinflammation. 2011; 8:39.
  39. Mostafa GA, Al-Ayadhi LY. The relationship between the increased frequency of serum antineuronal antibodies and the severity of autism in children. European journal of paediatric neurology. 2012; 16:464-468.
  40. Mostafa GA, Kitchener N. Serum anti-nuclear antibodies as a marker of autoimmunity in Egyptian autistic children. Pediatric neurology. 2009; 40:107-112.
  41. Singh VK, Warren R, Averett R, Ghaziuddin M. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatric neurology. 1997; 17:88-90.
  42. Singh VK, Warren RP, Odell JD, Warren WL, Cole P. Antibodies to myelin basic protein in children with autistic behavior. Brain, behavior, and immunity. 1993; 7:97-103.
  43. Mostafa GA, AL-Ayadhi LY. A lack of association between hyperserotonemia and the increased frequency of serum anti-myelin basic protein auto-antibodies in autistic children. Journal of neuroinflammation. 2011; 8:71.
  44. Mostafa GA, Awad El-Sayed Z, Mohamed Abd El-Aziz M, Farouk El-Sayed M. Serum anti-myelin?associated glycoprotein antibodies in Egyptian autistic children. Journal of child neurology. 2008; 23:1413-1418.
  45. Connolly AM, Chez M, Streif EM, Keeling RM, Golumbek PT, Kwon JM, Riviello JJ, Robinson RG, Neuman RJ, Deuel RM. Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biological psychiatry. 2006; 59:354-363.
  46. Taurines R, Segura M, Schecklmann M, Albantakis L, Gr?nblatt E, Walitza S, Jans T, Lyttwin B, Haberhausen M, Theisen FM, Martin B. Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder. Journal of Neural Transmission. 2014; 121:1117-1128.
  47. Kowal C, Athanassiou A, Chen H, Diamond B. Maternal antibodies and developing blood?brain barrier. Immunologic research. 2015; 63:18-25.
  48. Samuelsson AM, Jennische E, Hansson HA, Holm?ng A. Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABAA dysregulation and impaired spatial learning. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2006; 290:R1345-1356.
  49. Tordjman S, Somogyi E, Coulon N, Kermarrec S, Cohen D, Bronsard G, Bonnot O, Weismann-Arcache C, Botbol M, Lauth B, Ginchat V. Gene? Environment interactions in autism spectrum disorders: role of epigenetic mechanisms. Frontiers in psychiatry. 2014; 5:53.
  50. Oddi D, Crusio WE, D?Amato FR, Pietropaolo S. Monogenic mouse models of social dysfunction: implications for autism. Behavioural brain research. 2013; 251:75-84.
  51. Oberman LM. mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders. Expert opinion on investigational drugs. 2012; 21:1819-1825.
  52. Verpelli C, Montani C, Vicidomini C, Heise C, Sala C. Mutations of the synapse genes and intellectual disability syndromes. European journal of pharmacology. 2013; 719:112-116.
  53. Chia N, Wang L, Lu X, Senut MC, Brenner CA, Ruden DM. Hypothesis: environmental regulation of 5-hydroxymethylcytosine by oxidative stress. Epigenetics. 2011; 6:853-856.
  54. James SJ, Shpyleva S, Melnyk S, Pavliv O, Pogribny IP. Elevated 5-hydroxymethylcytosine in the Engrailed-2 (EN-2) promoter is associated with increased gene expression and decreased MeCP2 binding in autism cerebellum. Translational psychiatry. 2014; 4:e460.
  55. Castro GD, G?mez MI, Castro J. 5-Methylcytosine attack by hydroxyl free radicals and during carbon tetrachloride promoted liver microsomal lipid peroxidation: structure of reaction products. Chemico-biological interactions. 1996; 99:289-299.
  56. Brownstein MJ, Russell JT, Gainer H. Synthesis, transport, and release of posterior pituitary hormones. Science. 1980; 207:373-378.
  57. Ludwig M, Leng G. Dendritic peptide release and peptide-dependent behaviours. Nature Reviews Neuroscience. 2006; 7:126-136.
  58. Neumann ID. Brain oxytocin: a key regulator of emotional and social behaviours in both females and males. Journal of neuroendocrinology. 2008; 20:858-865.
  59. Ross HE, Young LJ. Oxytocin and the neural mechanisms regulating social cognition and affiliativebehavior. Frontiers in neuroendocrinology. 2009; 30:534-547.
  60. Russell JA, Leng G, Douglas AJ. The magnocellular oxytocin system, the fount of maternity: adaptations in pregnancy. Frontiers in neuroendocrinology. 2003; 24:27-61.
  61. Carter CS, Boone EM, Pournajafi-Nazarloo H, Bales KL. Consequences of early experiences and exposure to oxytocin and vasopressin are sexually dimorphic. Developmental neuroscience. 2009; 31:332-341.
  62. Guastella AJ, Mitchell PB, Dadds MR. Oxytocin increases gaze to the eye region of human faces. Biological psychiatry. 2008; 63:3-5.
  63. Ditzen B, Schaer M, Gabriel B, Bodenmann G, Ehlert U, Heinrichs M. Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biological psychiatry. 2009; 65:728-731.
  64. Zak PJ, Stanton AA, Ahmadi S. Oxytocin increases generosity in humans. PloS one. 2007; 2:e1128.
  65. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005; 435:673-676.
  66. Rimmele U, Hediger K, Heinrichs M, Klaver P. Oxytocin makes a face in memory familiar. Journal of Neuroscience. 2009; 29:38-42.
  67. Higashida H, Yokoyama S, Kikuchi M, Munesue T. CD38 and its role in oxytocin secretion and social behavior. Hormones and behavior. 2012; 61:351-358.
  68. Denu JM. Vitamin B 3 and sirtuin function. Trends in biochemical sciences. 2005; 30:479-483.
  69. Hammock EA, Young LJ. Functional microsatellite polymorphism associated with divergent social structure in vole species. Molecular biology and evolution. 2004; 21:1057-1063.
  70. vanWimersmaGreidanus TB, van Ree JM, de Wied D. Vasopressin and memory. Pharmacology & therapeutics. 1983; 20:437-458.
  71. Hu VW. Is retinoic acid-related orphan receptor-alpha (RORA) a target for gene?environment interactions contributing to autism?. Neurotoxicology. 2012; 33:1434-1435.
  72. Hu VW, Sarachana T, Kim KS, Nguyen A, Kulkarni S, Steinberg ME, Luu T, Lai Y, Lee NH. Gene expression profiling differentiates autism case?controls and phenotypic variants of autism spectrum disorders: Evidence for circadian rhythm dysfunction in severe autism. Autism research. 2009; 2:78-97.
  73. Nguyen A, Rauch TA, Pfeifer GP, Hu VW. Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain. The FASEB Journal. 2010; 24:3036-3051.
  74. Sarachana T, Xu M, Wu RC, Hu VW. Sex hormones in autism: androgens and estrogens differentially and reciprocally regulate RORA, a novel candidate gene for autism. PloS one. 2011; 6:e17116.
  75. Gold DA, Gent PM, Hamilton BA. RORα in genetic control of cerebellum development: 50 staggering years. Brain research. 2007; 1140:19-25.
  76. Hadj-Sahraoui N, Frederic F, Zanjani H, Delhaye-Bouchaud N, Herrup K, Mariani J. Progressive atrophy of cerebellar Purkinje cell dendrites during aging of the heterozygous staggerer mouse (Rora+/sg). Developmental Brain Research. 2001; 126:201-209.
  77. Boukhtouche F, Vodjdani G, Jarvis CI, Bakouche J, Staels B, Mallet J, Mariani J, Lemaigre‐Dubreuil Y, Brugg B. Human retinoic acid receptor‐related orphan receptor α1 overexpression protects neurones against oxidative stress‐induced apoptosis. Journal of neurochemistry. 2006; 96:1778-1789.
  78. Delerive P, Mont? D, Dubois G, Trottein F, Fruchart‐Najib J, Mariani J, Fruchart JC, Staels B. The orphan nuclear receptor RORα is a negative regulator of the inflammatory response. EMBO reports. 2001; 2:42-48.
  79. Sato F, Kawamoto T, Fujimoto K, Noshiro M, Honda KK, Honma S, Honma KI, Kato Y. Functional analysis of the basic helix‐loop‐helix transcription factor DEC1 in circadian regulation. European Journal of Biochemistry. 2004; 271:4409-4419.
  80. Gardener H, Spiegelman D, Buka SL. Prenatal risk factors for autism: comprehensive meta-analysis. The British journal of psychiatry. 2009; 195:7-14.
  81. Goines PE, Croen LA, Braunschweig D, Yoshida CK, Grether J, Hansen R, Kharrazi M, Ashwood P, Van de Water J. Increased midgestational IFN-γ, IL-4 and IL-5 in women bearing a child with autism: a case-control study. Molecular autism. 2011; 2:13.
  82. Cate PT, Ineke M. Prenatal maternal stress and child developmental outcome: implications for health care provision?. Developmental Medicine & Child Neurology. 2014; 56:204-205.
  83. Gardener H, Spiegelman D, Buka SL. Perinatal and neonatal risk factors for autism: a comprehensive meta-analysis. Pediatrics. 2011; peds-2010.
  84. Currenti SA. Understanding and determining the etiology of autism. Cellular and molecular neurobiology. 2010; 30:161-171.
  85. Almeras L, Eyles D, Benech P, Laffite D, Villard C, Patatian A, Boucraut J, Mackay‐Sim A, McGrath J, F?ron F. Developmental vitamin D deficiency alters brain protein expression in the adult rat: implications for neuropsychiatric disorders. Proteomics. 2007; 7:769-780.
  86. Moore ME, Piazza A, McCartney Y, Lynch MA. Evidence that vitamin D3 reverses age-related inflammatory changes in the rat hippocampus. Biochemical Society transactions. 2005; 573-577.
  87. Burne TH, F?ron F, Brown J, Eyles DW, McGrath JJ, Mackay-Sim A. Combined prenatal and chronic postnatal vitamin D deficiency in rats impairs prepulse inhibition of acoustic startle. Physiology &behavior. 2004; 81:651-655.
  88. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends in Endocrinology & Metabolism. 2002; 13:100-105.
  89. Kern JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in autism. Journal of Toxicology and Environmental Health, Part B. 2006; 9:485-499.
  90. Dean L. Blood Groups and Red Cell Antigens [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). Blood and the cells it contains. 2005.
  91. Bennett DJ, Ogloff JR, Mullen PE, Thomas SD, Wallace C, Short T. Schizophrenia disorders, substance abuse and prior offending in a sequential series of 435 homicides. ActaPsychiatricaScandinavica. 2011; 124:226-233.
  92. Fazel S, Gulati G, Linsell L, Geddes JR, Grann M. Schizophrenia and violence: systematic review and meta-analysis. PLoS Med. 2009; 6:e1000120.
  93. Large M, Smith G, Nielssen O. The relationship between the rate of homicide by those with schizophrenia and the overall homicide rate: a systematic review and meta-analysis. Schizophrenia research. 2009; 112:123-129.
  94. Nielssen O, Large M. Rates of homicide during the first episode of psychosis and after treatment: a systematic review and meta-analysis. Schizophrenia bulletin. 2010; 36:702-712.
  95. Bo S, Abu-Akel A, Kongerslev M, Haahr UH, Simonsen E. Risk factors for violence among patients with schizophrenia. Clinical psychology review. 2011; 31:711-726.
  96. Elbogen EB, Johnson SC. The intricate link between violence and mental disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of general Psychiatry. 2009; 66:152-161.
  97. Wallace C, Mullen P, Burgess P, Palmer S, Ruschena D, Browne C. Serious criminal offending and mental disorder. Case linkage study. The British Journal of Psychiatry. 1998; 172:477-484.
  98. McGuire J, Langdon R, Br?ne M. Moral cognition in schizophrenia. Cognitive neuropsychiatry. 2014; 19:495-508.
  99. Hamlyn J, Duhig M, McGrath J, Scott J. Modifiable risk factors for schizophrenia and autism?shared risk factors impacting on brain development. Neurobiology of disease. 2013; 53:3-9.
  100. Budimirovic DB, Kaufmann WE. What can we learn about autism from studying fragile X syndrome?. Developmental neuroscience. 2011; 33:379-394.
  101. Muhle R, Trentacoste SV, RapinI. The genetics of autism. Pediatrics. 2004; 113:e472-486.
  102. Schaefer GB, Mendelsohn NJ. Genetics evaluation for the etiologic diagnosis of autism spectrum disorders. Genetics in Medicine. 2008; 10:4-12.
  103. Cohen D, Pichard N, Tordjman S, Baumann C, Burglen L, Excoffier E, Lazar G, Mazet P, Pinquier C, Verloes A, H?ron D. Specific genetic disorders and autism: clinical contribution towards their identification. Journal of autism and developmental disorders. 2005; 35:103-116.
  104. Budimirovic DB, Bukelis I, Cox C, Gray RM, Tierney E, Kaufmann WE. Autism spectrum disorder in Fragile X syndrome: differential contribution of adaptive socialization and social withdrawal. American journal of medical genetics Part A. 2006; 140:1814-1826.
  105. Hatton DD, Sideris J, Skinner M, Mankowski J, Bailey DB, Roberts J, Mirrett P. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. American journal of medical genetics Part A. 2006; 140:1804-1813.
  106. Hernandez RN, Feinberg RL, Vaurio R, Passanante NM, Thompson RE, Kaufmann WE. Autism spectrum disorder in fragile X syndrome: a longitudinal evaluation. American Journal of Medical Genetics Part A. 2009; 149:1125-1137.
  107. Sabaratnam M, Murthy NV, Wijeratne A, Buckingham A, Payne S. Autistic-like behaviour profile and psychiatric morbidity in Fragile X Syndrome. European child & adolescent psychiatry. 2003; 12:172-177.
  108. Merenstein SA, Sobesky WE, Taylor AK, Riddle JE, Tran HX, Hagerman RJ. Molecular‐clinical correlations in males with an expanded FMR1 mutation. American Journal of Medical Genetics Part A. 1996; 64:388-394.
  109. Freund LS, Reiss AL, Abrams MT. Psychiatric disorders associated with fragile X in the young female. Pediatrics. 1993; 91:321-329.
  110. Bailey DB, Mesibov GB, Hatton DD, Clark RD, Roberts JE, Mayhew L. Autistic behavior in young boys with fragile X syndrome. Journal of autism and developmental disorders. 1998; 28:499-508.
  111. Cohen IL, Fisch GS, Sudhalter V, Wolf-Schein EG, Hanson D, Hagerman R, Jenkins EC, Brown WT. Social gaze, social avoidance, and repetitive behavior in fragile X males: a controlled study. American Journal on Mental Retardation. 1988 Mar.
  112. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, Picker J. Advances in the treatment of fragile X syndrome. Pediatrics. 2009; 123:378-390.
  113. Streck EL, Gon?alves CL, Furlanetto CB, Scaini G, Dal-Pizzol F, Quevedo J. Mitochondria and the central nervous system: searching for a pathophysiological basis of psychiatric disorders. RevistaBrasileira de Psiquiatria. 2014; 36:156-167.
  114. Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron. 2008; 60:748-766.
  115. Herrero-Mendez A, Almeida A, Fern?ndez E, Maestre C, Moncada S, Bola?os JP. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C?Cdh1. Nature cell biology. 2009; 11:747-752.
  116. Williams JM, Thompson VL, Mason-Parker SE, Abraham WC, Tate WP. Synaptic activity-dependent modulation of mitochondrial gene expression in the rat hippocampus. Molecular brain research. 1998; 60:50-56.
  117. Li Z, Jo J, Jia JM, Lo SC, Whitcomb DJ, Jiao S, Cho K, Sheng M. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Cell. 2010; 141:859-871.
  118. Sokol DK, Maloney B, Long JM, Ray B, Lahiri DK. Autism, Alzheimer disease, and fragile X APP, FMRP, and mGluR5 are molecular links. Neurology. 2011; 76:1344-1352.
  119. Frye RE, Delatorre R, Taylor H, Slattery J, Melnyk S, Chowdhury N, James SJ. Redox metabolism abnormalities in autistic children associated with mitochondrial disease. Translational psychiatry. 2013; 3:e273.
  120. Gurk-Turner C, Manitpisitkul W, Cooper M. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation. 2012; 94:659-668.
  121. Beecham JE, Seneff S. The possible link between autism and glyphosate acting as glycine mimetic?A review of evidence from the literature with analysis. Journal of molecular and genetic medicine. 2015; 9:4.
  122. Li X, Zou H, Brown WT. Genes associated with autism spectrum disorder. Brain research bulletin. 2012; 88:543-552.

[Kajal Singla, Abhinob Baruah, Shilpa S Chapadgaonkar and Nilanjan Das. (2017); A REVIEW ON APPROACHES TO DIAGNOSE THE AUTISM SPECTRUM DISORDER: THE NEED OF THE HOUR. Int. J. of Adv. Res. 5 (Oct). 695-709] (ISSN 2320-5407). www.journalijar.com

NILANJAN DAS

DOI:

Article DOI: 10.21474/IJAR01/5577      
DOI URL: https://dx.doi.org/10.21474/IJAR01/5577

Download Full Paper

Download PDF No. of Downloads: 41 | No. of Views: 235